As the life expectancy has increased in individuals with cerebral palsy, this has led to being able to assess the changes in the bio-psycho-social dimensions of their health.
The aim of the study is ...to describe the characteristics of individuals with cerebral palsy and to evaluate their functional situation.
Cross-sectional descriptive study conducted on a sample of 26 individuals between 27 and 65 years old with cerebral palsy. Data was collected during a semi-structured interview. The Cross Motor Function Classification System (GMFCS), the Manual Ability Classification System (MACS), and the Communication Function Classification System (CFCS), were used to evaluate the functional situation.
The profile of the adult seen in the Cerebral Palsy Association of Burgos, Spain, is male, over 40 years old, single, illiterate, with no professional qualification, lives in a residence, receives social benefit, and with great functional disability.
The functional capacity of people with cerebral palsy who are in adult care centres is low. It emphasises the low cultural level and the lack of professional qualification and all of them have a disability that limits their ability to perform daily activities, possibly related to the high mean age.
Sepiolite is a hydrate magnesium silicate special clay mineral. Some of the specific properties of this silicate are its large specific surface (about 320
m
2/g) together with a very reduced ion ...exchange capacity. Additionally, it is possible to leach the magnesium cations at the octahedral layer by acid attack, increasing the specific surface area up to the limit of the collapse of the structure. In the present investigation, we have found that the crystalline framework collapses when the fraction of leached Mg
2+ is greater than or equal to 0.33. Before the collapse it is possible to obtain sepiolite with different substituted metallic cations into the octahedral sites. As an example, the optimal composition of Ni–sepiolite was obtained after the lixiviation by acid attack at pH 0 for 1
h without the collapse of structure.
Summary
A high throughput screening for anticancer activity of FDA approved drugs identified mycophenolic acid (MPA), an inhibitor of inositol monophosphate dehydrogenase (IMPDH) as an active agent ...with an antiangiogenesis mode of action. Exposure of pancreatic cancer cell lines to MPA resulted in growth inhibition and reduced the expression of VEGF that was reversed by supplementing the media with guanosine supporting and IMPDH-dependant mechanism. In preclinical in vivo study, MPA showed a moderate inhibition of tumor growth in a panel of 6 human derived pancreatic cancer xenografts but reduced the expression of VEGF. To investigate the effects of MPA in human pancreatic cancer, a total of 12 patients with resectable pancreatic cancer (PDA) received increasing doses of mycophenolate mofetil (MMF) in cohorts of 6 patients each from 5–15 days prior to surgical resection. Treatment was well tolerated with one episode of grade 1 muscle pain, one episode of grade 2 lymphopenia (2 gr/day dose) and one episode of grade 2 elevantion in LFT (all in the 2 gr./day dose). Patients recovered from surgery uneventfully with no increased post-operative complications. Assessment of CD31, VEGF, and TUNEL in resected specimens compared to a non treated control of 6 patients showed no significant variations in any of the study endpoints. In conclusion, this study shows the feasibility of translating a preclinical observation to the clinical setting and to explore a drug mechanism of action in patients. MPA, however, did not show any hints of antiangiogenesis of anticancer clinical activity questioning if this agent should be further developed in PDA.
In preclinical studies trifluridine/tipiracil (FTD/TPI) plus oxaliplatin (Industriestrasse, Holzkirchen, Germany) sensitised microsatellite stable (MSS) metastatic colorectal cancer (mCRC) to ...anti-programmed cell death protein-1; the addition of oxaliplatin or bevacizumab (F Hoffmann- la ROCHE AG, Kaiseraugst, Switzerland) enhanced the antitumour effects of FTD/TPI. This study aimed to investigate the safety and efficacy of FTD/TPI plus oxaliplatin and either bevacizumab or nivolumab (Uxbridge business Park, Uxbridge, United Kingdom) in patients with mCRC who had progressed after at least one prior line of treatment.
In 14-day cycles, patients received FTD/TPI 35 mg/m2 (twice daily, days 1-5) plus oxaliplatin 85 mg/m2 (day 1), and, on day 1, either bevacizumab 5 mg/kg (cohort A) or nivolumab 3 mg/kg (cohort B). Patients in Cohort B had confirmed MSS status.
In total, 54 patients were enrolled: 37 in cohort A and 17 in cohort B. Recruitment in cohort B was stopped early due to the low response rate (RR) observed at interim analyses of efficacy. The most common adverse events (AEs) in cohort A were neutropenia/decreased neutrophils (75.7%), nausea (59.5%), vomiting (40.5%), diarrhoea (37.8%), peripheral sensory neuropathy (37.8%), fatigue (35.1%) and decreased appetite (35.1%). In cohort B, the most common AEs were neutropenia/decreased neutrophils (70.6%), diarrhoea (58.8%), nausea (47.1%), vomiting (47.1%), fatigue (47.1%), asthenia (41.2%), paraesthesia (41.2%), thrombocytopenia/decreased platelets (35.3%) and decreased appetite (35.3%). Confirmed objective RR was 17.1% in cohort A and 7.1% in cohort B; the corresponding values for median progression-free survival in the two cohorts were 6.3 and 6.0 months.
FTD/TPI plus oxaliplatin and bevacizumab or nivolumab had an acceptable safety profile and demonstrated antitumour activity in previously treated patients with mCRC.
•This study evaluated the safety and efficacy of FTD/TPI plus oxaliplatin and either bevacizumab or nivolumab in mCRC patients.•FTD/TPI plus oxaliplatin in combination with bevacizumab or nivolumab had an acceptable and manageable safety profile.•Antitumour activity was observed following treatment with FTD/TPI plus oxaliplatin and bevacizumab.•Despite a modest RR with the addition of nivolumab, survival data were promising in these poor-prognosis patients.
Homogeneous 10-30 nm gamma -Fe sub(2)O sub(3) (maghemite) nanoparticles have been synthesized on magnesium silicate fibers and further incorporated into a polymeric matrix (polystyrene). The ...similarity in the refractive indices of both materials (n sub(Sep) = 1.53 and n sub(PS) = 1.59) and the optimal dispersion allowed obtaining highly transparent composites from near IR to the visible range. Therefore, particles of gamma -Fe sub(2)O sub(3) appear perfectly dispersed inside a heterogeneous but transparent matrix, and consequently, it is possible to measure their Faraday rotation. These composites present a ferromagnetic behavior, yet close to superparmagnetism due to the size of the gamma -Fe sub(2)O sub(3) particles. High real in-line transmittance in the visible range together with a Faraday activity over 0.4degrees are obtained in 50 mu m films, which is over twice larger than that reported for commercially available devices based on single crystal terbium gallium garnets.
PDF
